The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index; 13 of the 35 sources its claims cite were checked for support.
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Open accessAbstract
Drug-induced liver injury (DILI) continues to be a major source of clinical attrition, precautionary warnings, and post-market withdrawal of drugs. Accordingly, there is a need for more predictive tools to assess hepatotoxicity risk in drug discovery. Three-dimensional (3D) spheroid hepatic cultures have emerged as promising tools to assess mechanisms of hepatotoxicity, as they demonstrate enhanced liver phenotype, metabolic activity, and stability in culture not attainable with conventional two-dimensional hepatic models. Increased sensitivity of these models to drug-induced cytotoxicity has been demonstrated with relatively small panels of hepatotoxicants. However, a comprehensive evaluation of these models is lacking. Here, the predictive value of 3D human liver microtissues (hLiMT) to identify known hepatotoxicants using a panel of 110 drugs with and without clinical DILI has been assessed in comparison to plated two-dimensional primary human hepatocytes (PHH). Compounds were treated long-term (14 days) in hLiMT and acutely (2 days) in PHH to assess drug-induced cytotoxicity over an 8-point concentration range to generate IC 50 values. Regardless of comparing IC 50 values or exposure-corrected margin of safety values, hLiMT demonstrated increased sensitivity in identifying known hepatotoxicants than PHH, while specificity was consistent across both assays. In addition, hLiMT out performed PHH in correctly classifying hepatotoxicants from different pharmacological classes of molecules. The hLiMT demonstrated sufficient capability to warrant exploratory liver injury biomarker investigation (miR-122, HMGB1, α -GST) in the cell-culture media. Taken together, this study represents the most comprehensive evaluation of 3D spheroid hepatic cultures up to now and supports their utility for hepatotoxicity risk assessment in drug discovery.
Overview
CoChat Summary
TL;DR
In a 110-drug retrospective panel, 3D human liver microtissues (hLiMT) detected more cytotoxicity IC50 values and showed greater sensitivity than plated 2D primary human hepatocytes (PHH) for identifying clinical DILI-positive compounds, with similar specificity. The hLiMT model also supported exploratory liver-injury biomarker measurement in culture supernatant.
Key findings
- hLiMT detected more IC50 values than PHH across the 110-drug set: 56/110 vs 40/110. Among DILI-positive compounds, no IC50 was determined for 33% (23/69) in hLiMT vs 54% (37/69) in PHH.
- At fixed IC50 thresholds, hLiMT sensitivity was higher at every threshold: at 10 μM, 18.8% (13/69) vs 4.3% (3/69); at 100 μM, 60.9% (42/69) vs 33.3% (23/69). Specificity at 100 μM was 85.4% for both assays; PLR was 4.16 for hLiMT vs 2.28 for PHH, and NLR was 0.46 vs 0.78.
- Using margin-of-safety (MOS = IC50/total plasma Cmax) thresholds, hLiMT again showed higher sensitivity: at 10× MOS, 36.2% (25/69) vs 20.3% (14/69), with specificity 97.6% for both and PLR 14.86 vs 8.32. At 100× MOS, sensitivity was 59.4% vs 40.6%, with specificity 80.5% vs 85.4%.
- hLiMT better distinguished some structurally related pairs: bosentan and sitaxsentan had MOS values of 12.5× and 8.7×, while ambrisentan was not detected; PHH detected no IC50 for any of the three endothelin-receptor antagonists. Exploratory biomarkers α-GST, HMGB1, and miR-122 were measurable in hLiMT supernatant after chlorpromazine exposure.
Methods
- A panel of 110 marketed drugs was classified into five DILI severity categories; categories 1–3 were considered DILI-positive (69 drugs) and categories 4–5 DILI-negative (41 drugs).
- Cytotoxicity was assessed by ATP-based CellTiter-Glo: plated 2D PHH were treated for 48 h, while 3D hLiMT (primary human hepatocytes co-cultured with non-parenchymal cells) were treated for 14 days with re-dosing; IC50 values were generated over an 8-point concentration range and exposure-corrected MOS values were calculated using total plasma Cmax.
- Predictive performance was evaluated with ROC analysis, fixed IC50 and MOS thresholds, Cohen’s kappa, and positive/negative likelihood ratios; reproducibility was tested across different NPC and hepatocyte lots, and exploratory biomarkers were measured in hLiMT culture media.
Limitations
- The paper states that hLiMT failed to properly classify approximately 40% of DILI-positive compounds; no cytotoxicity was observed for 23/69 DILI-positive drugs, and 28/69 DILI-positive compounds fell above a 100× MOS threshold. Many misclassified compounds were associated with low-incidence or idiosyncratic DILI.
- The paper notes that the hLiMT spheroids contain only approximately 1000 cells, which could limit sensitivity for secondary supernatant endpoints, although exploratory biomarkers were detected. It also states that it remained unclear whether enhanced predictive value was due to culture complexity, treatment duration, or other factors.
- Evident from the text: the ROC comparison using only compounds with IC50 values was biased by the different numbers of IC50 values obtained between assays, so the authors relied on fixed practical thresholds; these thresholds are somewhat arbitrary and assay performance depended on the compound set and concentration ranges achievable in vitro.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
9 Valid · 1 Not valid · 15 Not checked · 80 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Increased sensitivity of these models to drug-induced cytotoxicity has been demonstrated with relatively small panels of hepatotoxicants.”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Abstract
What the sources say
- Supportedcites Bell et al. 2016 source
The Discussion reports that long-term dosing enhanced the sensitivity of PHH spheroids to a panel of five hepatotoxins. The Results likewise report increased toxicity and lower EC50 values after prolonged exposure for all five compounds. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“These data are in agreement with the findings of Bell et al. (2016) who noted prolonged drug exposure of up to 28 days resulted in increased sensitivity for detection of DILI compounds amiodarone, bosentan, diclofenac, fialuridine, and tolcapone (Bell et al. 2016).”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Discussion
What the sources say
- Supportedcites Bell et al. 2016 source
The Results section (‘PHH spheroids are a suitable system to study chronic DILI’) reports testing all five named compounds after 48 hours, 8 days, and 28 days; prolonged exposure increased toxicity and reduced EC50 values for all five. The Discussion likewise describes enhanced sensitivity with long-term dosing. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, the potential of the 3D hLiMT to report on the release of novel translational in vivo liver hepatotoxicity biomarkers, miR-122, a highly liver specific microRNA (Wang et al. 2009), HMGB1, a marker of immune modulation and necrosis (Antoine et al. 2009), and α-GST, a sensitive, highly specific and early biomarker for hepatocellular injury (Muller and Dieterle 2009), following exposure”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Discussion
What the sources say
- Supportedcites Wang et al. 2009 source
The citation is attached specifically to the description of miR-122 as a highly liver-specific microRNA, not to the claim about the 3D hLiMT. The paper’s “Dose-and Duration-Dependent Changes on the Circulating miRNA” section says that miR-122 is highly restricted to the liver. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites Antoine et al. 2009 source
- Not checked — no full text of the sourcecites Muller and Dieterle 2009 source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Addition of extracellular bile acids in the cell-culture media caused increased cytotoxicity of liver spheroid cultures relative to normal media treated spheroid cultures treated with bosentan over 14 day (Hendriks et al. 2016).”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Discussion
What the sources say
- Supportedcites Hendriks et al. 2016 source
The Results section reports greater toxicity with bosentan plus bile acids than with bosentan alone in PHH and HepaRG spheroids. Its prolonged-exposure subsection says this synergistic toxicity was more pronounced after 14 days; the Discussion explicitly includes bosentan among the compounds tested over that period. The indexed passages provide no page numbers. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Based on the optimized thresholds for both IC50 and MOS values, both PHH and hLiMT exhibited similar sensitivity for detection of known DILI causing drugs, with values between 63 and 72% (data not shown).”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing ROC assessments
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
55 more claims
Create a free account to see all 105 claims and every source verdict.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This was almost double the sensitivity of 3D hepatic spheroids for the same drug set (42%) based on previously published data31,47,48”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“a preclinical model that is currently widely used in pharma and was only able to correctly identify 8 out of the 19 toxic drugs in the set (Table 5).”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the toxicities of these 8 drugs have been shown to be poorly predicted by hepatic spheroids31,32.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas the 3D hepatic spheroids did (only 67% specificity)31”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Proctor et al. (Proctor et al., 2017) showed that liver microtissues combining hepatocytes with HSCs, Kupffer, and endothelial cells outperformed 2D systems (87% sensitivity, 92% specificity) and better reflected clinical DILI data.”
From A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis (2026) · cites this paper as Proctor et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Introduction
“Using drug-induced cytotoxicity as an endpoint, hLiMT assay experienced increased sensitivity and specificity to identify known human hepatotoxicants in relation to plated PHH.”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing practical fixed thresholds
“| 3D hLiMT IC50 [μM] | 69 | 41 | 13 | 38 | 3 | 56 | 10 | 18.8 | 92.7 | 2.57 | 0.88 | 0.091 | 0.097 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing practical fixed thresholds
“| 2D PHH IC50 [μM] | 69 | 41 | 23 | 35 | 6 | 46 | 100 | 33.3 | 85.4 | 2.28 | 0.78 | 0.176 | 0.014 |”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing practical fixed thresholds
“| 2D PHH MOS (IC50/C max) | 69 | 41 | 23 | 35 | 6 | 46 | 50× | 33.3 | 85.4 | 2.28 | 0.78 | 0.156 | 0.031 |”
Citations
Cites
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398 · cited 1×
“In addition, the concordance of each assay with known DILI status was assessed using Cohen’s Kappa (Cohen 1960).”
MethodConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 3×
“…etiologies that encompass DILI (Chalasani et al. 2008), with unknown factors driving patient susceptibility towards hepatic stress and injury (Chalasani and Bjornsson 2010), coupled with the poor concordance of preclinical species to identify human hepatotoxicants in vivo (Olson et al. 2000).”
BackgroundStatistics Notes: Diagnostic tests 2: predictive values
Altman, D. G., & Bland, J. M. (1994) · BMJ · doi:10.1136/bmj.309.6947.102 · Cited by 1,711
Diagnostic tests 4: likelihood ratios
Deeks, J. J., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.329.7458.168 · Cited by 1,600 · cited 1×
“In addition, these parameters can be calculated directly from sensitivity and specificity estimates for tests that have binary results (Altman and Bland 1994a; Deeks and Altman 2004).”
BackgroundGodoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280 · cited 1×
“In most cases, these systems displayed enhanced metabolic activity, hepatocellular phenotype, and stability in culture, previously not attainable with traditional hepatic cell line or hepatocyte models [refer to review (Godoy et al. 2013)].”
BackgroundSelf-citationMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 4×
“…demonstrated increased CYP450 activity and improved stability of liver phenotype over time in culture compared to monocultures of primary hepatocytes (Khetani and Bhatia 2008), which was hypothesized to be driving in part the increased sensitivity towards hepatotoxicants (Khetani et al. 2013).”
BackgroundInfluentialCirculating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149 · cited 2×
“In addition, the potential of the 3D hLiMT to report on the release of novel translational in vivo liver hepatotoxicity biomarkers, miR-122, a highly liver specific microRNA (Wang et al. 2009), HMGB1, a marker of immune modulation and necrosis (Antoine et al.”
BackgroundDeterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting
Ma, X., Qu, X., Zhu, W., Li, Y.-S., Yuan, S., Zhang, H., Liu, J., Wang, P., Lai, C. S. E., Zanella, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524510113 · Cited by 872 · cited 1×
“…fibroblasts (Khetani and Bhatia 2008; Khetani et al. 2013), three-dimensional (3D) bioprinted liver tissues comprised of several hepatic cell types (Ma et al. 2016; Nguyen et al. 2016), and 3D spheroid cultures either as mono-culture or co-culture with hepatic non-parenchymal cells (NPC) (Bell et…”
BackgroundChalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755 · cited 3×
“This is not surprising in that DILI is comprised of many different etiologies and mechanisms, including factors that are both compound- and patient-related (Chalasani and Bjornsson 2010; Chalasani et al. 2008).”
BackgroundBell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739 · cited 16×
“2016), and 3D spheroid cultures either as mono-culture or co-culture with hepatic non-parenchymal cells (NPC) (Bell et al. 2016; Messner et al. 2013).”
BackgroundResultInfluential
Cited by
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design
Subbaiah, M. A. M., & Meanwell, N. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01215 · Cited by 710
Reproducing human and cross-species drug toxicities using a liver-chip
Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5516 · Cited by 511
“In other complex cell-based liver models including 3D human spheroid hepatic cultures, the IC50 was found to be more than 10-fold higher than in vivo (25).”
BackgroundSelf-citationInterconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies
Edington, C. D., Chen, W. L. K., Geishecker, E., Kassis, T., Soenksen, L. R., Bhushan, B. M., Freake, D., Kirschner, J., Maass, C., Tsamandouras, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22749-0 · Cited by 487
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., Fidock, M., Hamrén, B., Johnson, A., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 452
Self-citationHepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430
High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell–Derived Organoids
Shinozawa, T., Kimura, M., Cai, Y., Saiki, N., Yoneyama, Y., Ouchi, R., Koike, H., Maezawa, M., Zhang, R.-R., Dunn, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.002 · Cited by 378
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337
The evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration
Wang, H., Brown, P. C., Chow, E. C. Y., Ewart, L., Ferguson, S. S., Fitzpatrick, S., Freedman, B. S., Guo, G. L., Hedrich, W., Heyward, S., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13066 · Cited by 212
Self-citationA 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®
Bircsak, K. M., DeBiasio, R., Miedel, M., Alsebahi, A., Reddinger, R., Saleh, A., Shun, T., Vernetti, L. A., & Gough, A. (2021) · Toxicology · doi:10.1016/j.tox.2020.152667 · Cited by 192
Vorrink, S. U., Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy058 · Cited by 187
“…of the Presented Spheroid Platform With Previously Published PHH Systems 2Dsw MPCC Spheroid models References Xu et al. (2008) Khetani et al. (2013) Proctor et al. (2017) This study Exposure time 24 h 9 days 14 days 14 days Tested compounds (DILI positive/DILI negative) 344 (200/144) 45 (35/10)…”
BackgroundMethodBioengineered Liver Models for Drug Testing and Cell Differentiation Studies
Underhill, G. H., & Khetani, S. R. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.11.012 · Cited by 171
Bioprinting of Multiscaled Hepatic Lobules within a Highly Vascularized Construct
Kang, D., Hong, G., An, S., Jang, I., Yun, W., Shim, J., & Jin, S. (2020) · Small · doi:10.1002/smll.201905505 · Cited by 164
Holden, J. K., Crawford, J. J., Noland, C. L., Schmidt, S., Zbieg, J. R., Lacap, J. A., Zang, R., Miller, G. M., Zhang, Y., Beroza, P., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107809 · Cited by 161
Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00768g · Cited by 150
Self-citationLauschke, V. M., Shafagh, R. Z., Hendriks, D. F. G., & Ingelman‐Sundberg, M. (2019) · Biotechnology Journal · doi:10.1002/biot.201800347 · Cited by 153
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Cuvellier, M., Ezan, F., Oliveira, H., Rose, S., Fricain, J.-C., Langouët, S., Legagneux, V., & Baffet, G. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120611 · Cited by 126
Predicting Drug-Induced Liver Injury with Bayesian Machine Learning
Williams, D. P., Lazic, S. E., Foster, A. J., Semenova, E., & Morgan, P. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00264 · Cited by 124
Self-citationIndividual Control and Quantification of 3D Spheroids in a High-Density Microfluidic Droplet Array
Tomasi, R. F.-X., Sart, S., Champetier, T., & Baroud, C. N. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107670 · Cited by 128
“The biological function is enhanced in spheroids compared with 2D cultures (Bartosh et al., 2010; Proctor et al., 2017; Bell et al., 2018; Vorrink et al., 2018), while cells have been shown to produce their own ECM and interact with it (Wang et al.”
BackgroundHuman biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
Foster, A. J., Chouhan, B., Regan, S. L., Rollison, H., Amberntsson, S., Andersson, L. C., Srivastava, A., Darnell, M., Cairns, J., Lazic, S. E., et al. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02427-4 · Cited by 117
“First, they needed to be sensitive enough when using only 1500 cells in the hepatic spheroid (Proctor et al. 2017).”
BackgroundInfluentialSelf-citationPredictive validity in drug discovery: what it is, why it matters and how to improve it
Scannell, J. W., Bosley, J., Hickman, J. A., Dawson, G. R., Truebel, H., Ferreira, G. S., Richards, D. B., & Treherne, J. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00552-x · Cited by 142
“Of course, these correlations are rarely measured in practice, but for empirical examples of correlations between decision tools, or between decision tools and clinical utility in patients, see refs.(146,147,260).”
BackgroundFabre, K., Berridge, B., Proctor, W. R., Ralston, S., Will, Y., Baran, S. W., Yoder, G., & Van Vleet, T. R. (2020) · Lab on a Chip · doi:10.1039/c9lc01168d · Cited by 116
Self-citationAlbrecht, W., Kappenberg, F., Brecklinghaus, T., Stöber, R. M., Marchan, R., Zhang, M., Ebbert, K. E., Kirschner, H., Grinberg, M., Leist, M., et al. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02492-9 · Cited by 126
Ware, B. R., Durham, M., Monckton, C. P., & Khetani, S. R. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.11.007 · Cited by 111
“Thus, because of such limitations, collagen I gel–based liver models are not routinely used in pharmaceutical practice.(39,40) Ultimately, our approach/model is human-specific and is more amenable to high-throughput applications in the drug development pipeline.”
BackgroundA high-throughput imaging and nuclear segmentation analysis protocol for cleared 3D culture models
Boutin, M. E., Voss, T. C., Titus, S. A., Cruz-Gutierrez, K., Michael, S., & Ferrer, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-29169-0 · Cited by 97
Introducing an automated high content confocal imaging approach for Organs-on-Chips
Peel, S. E., Corrigan, A. M., Ehrhardt, B., Jang, K., Caetano-Pinto, P., Boeckeler, M., Rubins, J. E., Kodella, K. R., Petrópolis, D. B., Ronxhi, J., et al. (2019) · Lab on a Chip · doi:10.1039/c8lc00829a · Cited by 99
Self-citationTowards in vitro models for reducing or replacing the use of animals in drug testing
Stresser, D. M., Kopec, A. K., Hewitt, P., Hardwick, R. N., Van Vleet, T. R., Mahalingaiah, P. K. S., O’Connell, D., Jenkins, G. J., David, R., Graham, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01154-7 · Cited by 94
Baze, A., Parmentier, C., Hendriks, D. F. G., Hurrell, T., Heyd, B., Bachellier, P., Schuster, C., Ingelman‐Sundberg, M., & Richert, L. (2018) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2018.0134 · Cited by 103
“It thus allows the development of more integrated coculture model systems, with addition of LSECs, KCs, and HSCs to PHHs and indeed, some success in integration of either purified KCs 28 or crude NPCs 7,9 together with PHHs into 3D spheroids have been reported.”
Walker, P., Ryder, S., Lavado, A., Dilworth, C., & Riley, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02763-w · Cited by 100
A comprehensive review on 3D tissue models: Biofabrication technologies and preclinical applications
Xie, R., Pal, V., Yu, Y., Lu, X., Gao, M., Liang, S., Huang, M., Peng, W., & Ozbolat, I. T. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122408 · Cited by 119
Immune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
Zhou, Y., Shen, J. X., & Lauschke, V. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01093 · Cited by 85
Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis
Hurrell, T., Kastrinou‐Lampou, V., Fardellas, A., Hendriks, D. F. G., Nordling, Å., Johansson, I., Baze, A., Parmentier, C., Richert, L., & Ingelman‐Sundberg, M. (2020) · Cells · doi:10.3390/cells9040964 · Cited by 88
Lee, G., Kim, H., Park, J. Y., Kim, G., Han, J., Chung, S. H., Yang, J. H., Jeon, J. S., Woo, D., Han, C., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120529 · Cited by 81
Stem Cells for Next Level Toxicity Testing in the 21st Century
Fritsche, E., Haarmann‐Stemmann, T., Kapr, J., Galanjuk, S., Hartmann, J., Mertens, P. R., Kämpfer, A. A. M., Schins, R. P. F., Tigges, J., & Koch, K. (2020) · Small · doi:10.1002/smll.202006252 · Cited by 79
Liver three-dimensional cellular models for high-throughput chemical testing
Yang, S., Ooka, M., Margolis, R. J., & Xia, M. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100432 · Cited by 75
Dirven, H. A. A. M., Vist, G. E., Bandhakavi, S., Mehta, J., Fitch, S., Pound, P., Ram, R., Kincaid, B., Leenaars, C. H. C., Chen, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85708-2 · Cited by 80
Messner, S., Fredriksson, L., Lauschke, V. M., Roessger, K., Escher, C., Bober, M., Kelm, J. M., Ingelman‐Sundberg, M., & Moritz, W. (2017) · Applied In Vitro Toxicology · doi:10.1089/aivt.2017.0022 · Cited by 83
“In addition, the 3D liver spheroids proved suitable for reflecting liver pathologies, such as cholestasis, steatosis, and viral hepatitis,(45,55) as well as for prediction of DILI.(23,45)”
Self-citationLi, F., Cao, L., Parikh, S., & Zuo, R. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.02.021 · Cited by 72
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Ekert, J. E., Deakyne, J., Pribul-Allen, P., Terry, R., Schofield, C., Jeong, C. G., Storey, J., Mohamet, L., Francis, J., Naidoo, A., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220923332 · Cited by 68
“To perform genome-editing studies, capabilities in robust cellular models require extensive analysis of gene expression in human tissue [laser capture microdissection (LCM), single-cell technologies, spatial transcriptomics, and proteomics] to enable (1) data-driven decisions on cell model relevance, (2) expansive mul…”
MethodReardon, A. J. F., Farmahin, R., Williams, A., Meier, M. J., Addicks, G. C., Yauk, C. L., Matteo, G., Atlas, E., Harrill, J., Everett, L. J., et al. (2023) · Frontiers in Toxicology · doi:10.3389/ftox.2023.1194895 · Cited by 85
“Furthermore, immortalized cell lines are generally maintained in vitro in a monolayer or in suspension, whereas microtissues using 3D models containing multiple cell types better reflect in vivo characteristics (Proctor et al., 2017; Reardon et al., 2021; Rowan-Carroll et al., 2021).”
BackgroundDocci, L., Milani, N., Ramp, T., Romeo, A. A., Godoy, P., Franyuti, D. O., Krähenbühl, S., Gertz, M., Galetin, A., Parrott, N. J., et al. (2022) · Lab on a Chip · doi:10.1039/d1lc01161h · Cited by 74
Primary Human Hepatocyte Spheroid Model as a 3D In Vitro Platform for Metabolism Studies
Kanebratt, K. P., Janefeldt, A., Vilén, L., Vildhede, A., Samuelsson, K., Milton, L., Björkbom, A., Persson, M., Leandersson, C., Andersson, T. B., et al. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.10.043 · Cited by 66
Hepatic spheroids used as an in vitro model to study malaria relapse
Chua, A. C. Y., Ananthanarayanan, A., Ong, J. J. Y., Wong, J. Y., Yip, A., Singh, N. H., Qu, Y., Dembélé, L., McMillian, M., Ubalee, R., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.05.032 · Cited by 65
“The development and use of the 3D spheroid-culture hepatocyte model has accelerated in recent years, driven primarily by toxicology and metabolism studies [36,55,56].”
MethodBioengineering Organs for Blood Detoxification
Legallais, C., Kim, D., Mihaila, S. M., Mihajlovic, M., Figliuzzi, M., Bonandrini, B., Salerno, S., Yengej, F. A. Y., Rookmaaker, M. B., Romero, N. S., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800430 · Cited by 70
3D human liver spheroids for translational pharmacology and toxicology
Ingelman‐Sundberg, M., & Lauschke, V. M. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13587 · Cited by 62
Application of new approach methodologies for nonclinical safety assessment of drug candidates
Beilmann, M., Adkins, K., Boonen, H. C. M., Hewitt, P. G., Hu, W., Mader, R., Moore, S., Rana, P., Steger‐Hartmann, T., Villenave, R., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01182-9 · Cited by 85
“For example, a DILI screen using 110 marketed drugs demonstrated that 3D liver spheroids were superior to 2D primary hepatocytes in terms of sensitivity and specificity 132 .”
Optimizing drug discovery by Investigative Toxicology: Current and future trends
Beilmann, M., Boonen, H., Czich, A., Dear, G., Hewitt, P., Mow, T., Newham, P., Oinonen, T., Pognan, F., Roth, A., et al. (2018) · ALTEX · doi:10.14573/altex.1808181 · Cited by 85
“been demonstrated for various types of approaches in hepatocyte models including 3D spheroids (Messner et al., 2013; Bell et al., 2016; Proctor et al., 2017), 3D printed systems (Retting et al.”
BackgroundKammerer, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910214 · Cited by 59
“Overall, specificity of spheroids for detection of hepatotoxic substances was high (79–85%), and sensitivity was moderate (19–61%) indicating that also NPC containing spheroid cultures of pHHs are suitable for hepatotoxicity risk assessment in drug development processes and for the study of toxicity mechanisms [69,70].”
BackgroundHendriks, D. F. G., Vorrink, S. U., Smutny, T., Sim, S. C., Nordling, Å., Ullah, S., Kumondai, M., Jones, B. C., Johansson, I., Andersson, T. B., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1860 · Cited by 57
“CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 108 NUMBER 4 | October 2020 853 in vivo translation accuracy of more conventional 2D culture systems and underscore the added value of more complex 3D culture systems as already observed for predictions of other drug actions, such as hepatotoxicity.(25,32,33) The mechanism…”
BackgroundBell, C. C., Chouhan, B., Andersson, L. C., Andersson, H., Dear, J. W., Williams, D. P., & Söderberg, M. P. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02682-w · Cited by 65
Self-citationAleo, M. D., Shah, F., Allen, S. W., Barton, H. A., Costales, C., Lazzaro, S., Leung, L. Y., Nilson, A. L., Obach, R. S., Rodrigues, A. D., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00262 · Cited by 58
Cox, C. R., Lynch, S., Goldring, C. E., & Sharma, P. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.611913 · Cited by 68
“liver microtissues) treated for 14 days have greater sensitivity to detect DILI-positive compounds, with comparable specificity (32).”
BackgroundStröbel, S., Kostadinova, R. M., Fiaschetti‐Egli, K., Rupp, J., Bieri, M., Pawłowska, A., Busler, D., Hofstetter, T., Sanchez, K., Grepper, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01951-7 · Cited by 62
Self-citationGeneration of multi-cellular human liver organoids from pluripotent stem cells
(2020) · Methods in Cell Biology · doi:10.1016/bs.mcb.2020.03.009 · Cited by 55
Youhanna, S. C., Kemas, A. M., Preiss, L. C., Zhou, Y., Shen, J. X., Cakal, S. D., Paqualini, F. S., Goparaju, S. K., Shafagh, R. Z., Lind, J. U., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000238 · Cited by 67
Application of zebrafish to safety evaluation in drug discovery
Miyawaki, I. (2020) · Journal of Toxicologic Pathology · doi:10.1293/tox.2020-0021 · Cited by 60
Lee-Montiel, F. T., Laemmle, A., Charwat, V., Lee, C. S., Huebsch, N., Huebsch, N., Okochi, H., HANCOCK, M. J., Siemons, B. A., Boggess, S. C., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.667010 · Cited by 69
“Animal models perform variably in representing human diseases and predicting toxicity to humans due to inter-species differences in drug absorption, distribution, metabolism, excretion, and/or toxicity (ADME/Tox) (Jianling and Suzanne, 2009; Scott et al., 2013; Proctor et al., 2017).”
Hiemstra, S. W., Ramaiahgari, S., Wink, S., Callegaro, G., Coonen, M. L. J., Meerman, J. H. N., Jennen, D. G. J., van den Nieuwendijk, K., Dankers, A. C. A., Snoeys, J., et al. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02552-0 · Cited by 57
“The application of 3D spheroids for primary human hepatocytes has recently been systematically evaluated both assessment of adverse drug response and DILI liability (Bell et al. 2016; Proctor et al. 2017) as well as more recently to replicate disease states (Hendriks et al.”
BackgroundHu, C., Yang, S., Zhang, T., Ge, Y., Chen, Z., Zhang, J., Pu, Y., & Liang, G. (2024) · Environment International · doi:10.1016/j.envint.2024.108415 · Cited by 61
Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs
Leeson, P. D. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00044 · Cited by 57
Belair, D. G., Visconti, R. J., Hong, M., Marella, M., Peters, M. F., Scott, C. W., & Kolaja, K. L. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104928 · Cited by 54
Characterization of hepatocyte-based in vitro systems for reliable toxicity testing
Vinken, M., & Hengstler, J. G. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2297-6 · Cited by 60
Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes
Gu, X., Albrecht, W., Edlund, K., Kappenberg, F., Rahnenführer, J., Leist, M., Moritz, W., Godoy, P., Cadenas, C., Marchan, R., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2302-0 · Cited by 61
Shen, J. X., Youhanna, S. C., Shafagh, R. Z., Kele, J., & Lauschke, V. M. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00245 · Cited by 51
Three-dimensional liver models: state of the art and their application for hepatotoxicity evaluation
Zhang, X. “., Jiang, T., Chen, D., Wang, Q., & Zhang, L. W. (2020) · Critical Reviews in Toxicology · doi:10.1080/10408444.2020.1756219 · Cited by 60
Addicks, G. C., Rowan‐Carroll, A., Reardon, A. J. F., Leingartner, K., Williams, A., Meier, M. J., Moffat, I. D., Carrier, R., Lorusso, L., Wetmore, B. A., et al. (2023) · Toxicological Sciences · doi:10.1093/toxsci/kfad044 · Cited by 59
“These spheroids are a coculture model from 10 different human liver donors including males and females and are a metabolically active system of hepatocytes and Kupffer cells (Proctor et al., 2017; Rowan-Carroll et al., 2021).”
BackgroundZheng, Y., Ma, L.-D., Wu, J., Wang, Y., Meng, X., Hu, P., Liang, Q., Xie, Y., & Luo, G. (2022) · Talanta · doi:10.1016/j.talanta.2022.123262 · Cited by 51
The Promise of AI for DILI Prediction
Vall, A., Sabnis, Y. A., Shi, J., Class, R., Hochreiter, S., & Klambauer, G. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.638410 · Cited by 54
“Similarly, Proctor et al. (2017) built a classi fi er by selecting a threshold for each assay such that the resulting ROC curves were optimized.”
BackgroundMethodA Pillar and Perfusion Plate Platform for Robust Human Organoid Culture and Analysis
Kang, S., Kimura, M., Shrestha, S., Lewis, P., Lee, S., Cai, Y., Joshi, P., Acharya, P., Liu, J., Yang, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302502 · Cited by 44
Kelm, J. M., Lal‐Nag, M., Sittampalam, G. S., & Ferrer, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.07.007 · Cited by 45
Self-citationHuman liver model systems in a dish
Thompson, W. L., & Takebe, T. (2021) · Development Growth & Differentiation · doi:10.1111/dgd.12708 · Cited by 60
“…2019; Kim et al., 2015; Luo et al., 2018; Ma et al., 2016; Meier et al., 2017; Messner et al., 2013; Nagata et al., 2020; Pettinato et al., 2019; Proctor et al., 2017; Ramasamy et al., 2013; Schyschka et al., 2013; Sendi et al., 2018; Takayama et al., 2013; Tasnim et al., 2016; Vorrink et al.,…”
Extrapolating from acute to chronic toxicity in vitro
Macko, P., Palosaari, T., & Whelan, M. (2021) · Toxicology in Vitro · doi:10.1016/j.tiv.2021.105206 · Cited by 51
Hengstler, J. G., Sjogren, A.-K. M., Zink, D., & Hornberg, J. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02669-7 · Cited by 43
In vitro functional models for human liver diseases and drug screening: beyond animal testing
Paradiso, A., Volpi, M., Rinoldi, C., Celikkin, N., Contessi Negrini, N., Bilgen, M., Dallera, G., Pierini, F., Costantini, M., Święszkowski, W., et al. (2023) · Biomaterials Science · doi:10.1039/d1bm01872h · Cited by 40
Signore, M. A., Pascali, C. D., Giampetruzzi, L., Siciliano, P. A., & Francioso, L. N. (2021) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2021.100443 · Cited by 44
In Vitro Cancer Models: A Closer Look at Limitations on Translation
Antunes, N., Kundu, B., Kundu, S. C., Reis, R. L., & Correlo, V. M. (2022) · Bioengineering · doi:10.3390/bioengineering9040166 · Cited by 45
Tenogenic Properties of Mesenchymal Progenitor Cells Are Compromised in an Inflammatory Environment
Brandt, L., Schubert, S., Scheibe, P., Brehm, W., Franzen, J., Gross, C., & Burk, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092549 · Cited by 40
“It has also been shown that cells are more sensitive regarding the cytotoxicity of different substances when cultured in three-dimensional conditions, demonstrating that drug testing in a standard monolayer cultures alone is not predictive enough for in vivo toxicity [38].”
Safety Considerations in the Development of Hippo Pathway Inhibitors in Cancers
Kakiuchi-Kiyota, S., Schutten, M. M., Zhong, Y., Crawford, J. J., & Dey, A. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00156 · Cited by 42
Bajaj, P., Chung, G., Pye, K., Yukawa, T., Imanishi, A., Takai, Y., Brown, C., & Wagoner, M. P. (2020) · Toxicology · doi:10.1016/j.tox.2020.152535 · Cited by 39
Xiao, R., Lv, T., Tu, X., Li, P., Wang, T., Dong, H., Tu, P., & Ai, X. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27931 · Cited by 38
“Compared with a previous report of 2D PHH model, the 3D PHH model containing 122 clinical drugs exhibited increased sensitivity using all thresholds (Proctor et al., 2017).”
BackgroundMethodResultInfluentialEwart, L. C., Apostolou, A. P., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K., Joshipura, S. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472674 · Cited by 36
Kim, M. K., Jeong, W., Jeon, S., & Kang, H.-W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1305023 · Cited by 38
The Material World of 3D‐Bioprinted and Microfluidic‐Chip Models of Human Liver Fibrosis
Carvalho, A. M., Bansal, R., Barrias, C. C., & Sarmento, B. F. C. C. (2023) · Advanced Materials · doi:10.1002/adma.202307673 · Cited by 38
A Framework for Optimizing High-Content Imaging of 3D Models for Drug Discovery
Wardwell-Swanson, J. A., Suzuki, M., Dowell, K. G., Bieri, M., Thoma, E., Agarkova, I., Chiovaro, F., Strebel, S., Buschmann, N., Greve, F., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220929291 · Cited by 37
“5 In addition, multi-cellular 3D spheroid models can also be engineered to replicate complex disease states to more effectively interrogate and predict human responses to new therapies.”
BackgroundSaxton, S. H., & Stevens, K. R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.022 · Cited by 40
Baker, T. K., Vleet, T. R. V., Mahalingaiah, P. K. S., Grandhi, T. S. P., Evers, R., Ekert, J. E., Gosset, J. R., Chacko, S. A., & Kopec, A. K. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001510 · Cited by 42
Basharat, A., Rollison, H. E., Williams, D. P., & Ivanov, D. P. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115279 · Cited by 38
Self-citationHuman Three-Dimensional Hepatic Models: Cell Type Variety and Corresponding Applications
Xu, Q. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.730008 · Cited by 39
A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity
Kuepfer, L., Clayton, O., Thiel, C., Cordes, H., Nudischer, R., Blank, L. M., Baier, V., Heymans, S. R. B., Caiment, F., Roth, A. B., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2041-7 · Cited by 35
“Within HeCaToS, 3D liver and heart microtissues are used to account for different organ specific manifestations of drug-induced injuries such as cardiomyopathy, mitochondrial dysfunction or cholestasis (Beauchamp et al. 2015; Proctor et al. 2017).”
BackgroundSelf-citationMcKerrall, S. J., Nguyen, T. T., Lai, K. W., Bergeron, P., Deng, L., DiPasquale, A. G., Chang, J. H., Chen, J., Chernov-Rogan, T., Hackos, D. H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00141 · Cited by 38
Self-citationDo In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?
Kenna, J. G., & Uetrecht, J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.082719 · Cited by 32
Sun, B., Liang, Z., Wang, Y., Yu, Y., Zhou, X., Geng, X., & Li, B. (2024) · Toxicology · doi:10.1016/j.tox.2024.153829 · Cited by 30
Mechanisms of Chronic Fialuridine Hepatotoxicity as Revealed in Primary Human Hepatocyte Spheroids
Hendriks, D. F. G., Hurrell, T., Riede, J., van der Horst, M., Tuovinen, S., & Ingelman-Sundberg, M. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz195 · Cited by 29
Application of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery
Williams, D. P. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0228 · Cited by 29
Self-citationJiang, J., Pieterman, C., Ertaylan, G., Peeters, R., & de Kok, T. M. C. M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02585-5 · Cited by 34
Sheng, Q., Liu, B., Wang, X. D., Hua, L., Zhao, S.-C., Sun, X.-Z., Li, M., Zhang, X., Wang, J.-X., & Hu, P.-L. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04169-y · Cited by 40
“%) and glutathione depletion kinetics (3.2-fold sensitivity compared to 2D cultures) closely mirrored clinical toxicity profile (Jang et al. 2019; Proctor et al. 2017; Yanguas et al. 2016).”
Influential
Metadata
- Authors
- Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., Morgan, P., Messner, S., & Williams, D.
- Affiliations
- Genentech (US)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Foster, Alison J.
- Venue
- Archives of Toxicology
- Published
- 2017-06-13
- Volume
- 91
- Issue
- 8
- Pages
- 2849-2863
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- PMC
- PMC5515971
- OpenAlex
- W2625311319
- Cited by
- 328
- References
- 52
- Citations by year
- 2026: 30 · 2025: 49 · 2024: 33 · 2023: 29 · 2022: 33 · 2021: 33 · 2020: 49 · 2019: 35 · 2018: 31 · 2017: 6
- FWCI
- 35.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Archives of Toxicology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- drug-induced liver injury, hepatotoxicity prediction, primary human hepatocytes, drug cytotoxicity, IC50, safety margin, liver injury biomarkers, miR-122, HMGB1, alpha-glutathione S-transferase
- MeSH terms
- Humans, Liver, Predictive Value of Tests, Time Factors, Drug Design, Biomarkers, Risk Assessment, Inhibitory Concentration 50, Hepatocytes, Drug Discovery, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.